Recent findings have associated aberrant Sox2 expression with tumorigenesis in diverse cancers, including bladder cancer (Amini et al., 2014; Zhu et al., 2017), breast cancer (Rodriguez-Pinilla et al., 2007), colorectal cancer (Han et al., 2012; Amini et al., 2014), gastric cancer (Li et al., 2004), glioma (Alonso et al., 2011; Fang et al., 2011), osteosarcoma (Basu-Roy et al., 2012), pancreatic cancer (Sanada et al., 2006), prostate cancer (Amini et al., 2014), and skin squamous cell carcinoma (Boumahdi et al., 2014). This evidence concerns the gene SOX2 and cancer.